BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...

Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of ...

Emergent BioSolutions Inc. (NYSE:EBS), currently trading at $9.43 and showing a remarkable 356% return over the past year, announced today that its President and CEO, Joe C. Papa, presented at the ...

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between ...

(RTTNews) - Emergent BioSolutions (EBS), a life sciences company, on Tuesday announced that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada for ...

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC's support for the MOSA, a pan-African randomized platform ad ...